Liftstream is an executive search recruitment company in the life sciences sector
This article was authored by Karl Simpson, CEO and Founder, Liftstream, a company providing executive search services to the life sciences sector.
Albumedix A/S announced on January 4th 2017 that it has appointed Dr. Giles Campion as Chief Medical Officer (CMO). Dr Campion brings with him more than 25 years’ experience in drug development from both large pharma and biotech companies having worked in senior development positions in the US as well as Europe.
Tris Pharma, a pharmaceutical company based in Monmouth Junction, New Jersey, has appointed Sharon Clarke to the position of Chief Commercial Officer to lead the firm’s brand business and launch its first commercial product. The firm has a robust portfolio of approved New Drug Applications and late-stage pipeline of innovative technology based product candidates for the treatment of Attention-Deficit Hyperactivity Disorder.
PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company head-quartered in Malvern, PA, has appointed John Lee as Chief Medical Officer based in Malvern and John Sharp as Chief Financial officer based in San Diego.
Adaptive Biotechnologies, a sequencing and bioinformatics company based in Seattle, Washington, has appointed Diego Miralles as president of Adaptive Therapeutics. Miralles will build the Therapeutics Division of Adaptive, and head the company’s efforts to leverage its platform for identifying T- and B-cell receptors for use in therapies. He will provide both scientific and commercial guidance to the existing and future programs and partnerships that Adaptive is implementing
Amplyx Pharmaceuticals, a San Diego-based company developing antifungal agents for the treatment of life-threatening fungal infections, has appointed Michael Hodges as chief medical officer, Karen Shaw as vice president of biology, and Elizabeth Gordon as vice president of regulatory affairs. The firm recently raised an USD8.7 million investment from 3×5 Partners, increasing its series B financing to USD49.2 million.
HemaFlo Therapeutics, a private biotech company based in Carlsbad, Calif, has appointed Michael A. Martino as President, CEO and Board Director. Martino joined as President and CEO of Ambit Biosciences after its acquisition by Daiichi Sankyo in 2014.
AVROBIO, a clinical-stage biotechnology company developing transformative cell and gene therapies targeting cancer and rare diseases, has made three senior appointments. Joining the firm’s leadership team are Kim Warren, Head of Operations, Chris Mason, Chief Science Officer, and Deanna Petersen, Chief Business Officer.
Tocagen, a clinical-stage, cancer-selective gene therapy company, has named John Wood vice president of regulatory affairs and quality assurance.